- Home
- NBTX vs DMAC Comparison
NBTX vs DMAC Comparison
Compare NBTX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- DMAC
- Stock Information
- Founded
- NBTX 2003
- DMAC 2000
- Country
- NBTX France
- DMAC United States
- Employees
- NBTX N/A
- DMAC N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- DMAC Health Care
- Exchange
- NBTX Nasdaq
- DMAC Nasdaq
- Market Cap
- NBTX 201.9M
- DMAC 172.7M
- IPO Year
- NBTX 2020
- DMAC N/A
- Fundamental
- Price
- NBTX $3.83
- DMAC $4.18
- Analyst Decision
- NBTX Strong Buy
- DMAC Strong Buy
- Analyst Count
- NBTX 2
- DMAC 3
- Target Price
- NBTX $11.50
- DMAC $7.00
- AVG Volume (30 Days)
- NBTX 8.8K
- DMAC 46.2K
- Earning Date
- NBTX 11-26-2024
- DMAC 11-13-2024
- Dividend Yield
- NBTX N/A
- DMAC N/A
- EPS Growth
- NBTX N/A
- DMAC N/A
- EPS
- NBTX N/A
- DMAC N/A
- Revenue
- NBTX $45,220,186.00
- DMAC N/A
- Revenue This Year
- NBTX N/A
- DMAC N/A
- Revenue Next Year
- NBTX N/A
- DMAC N/A
- P/E Ratio
- NBTX N/A
- DMAC N/A
- Revenue Growth
- NBTX 526.17
- DMAC N/A
- 52 Week Low
- NBTX $3.57
- DMAC $2.14
- 52 Week High
- NBTX $8.96
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- NBTX 38.67
- DMAC 48.23
- Support Level
- NBTX $3.57
- DMAC $3.96
- Resistance Level
- NBTX $4.11
- DMAC $4.21
- Average True Range (ATR)
- NBTX 0.28
- DMAC 0.18
- MACD
- NBTX -0.00
- DMAC -0.02
- Stochastic Oscillator
- NBTX 26.31
- DMAC 50.00
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.